Piramal Pharma Solutions has confirmed that it has put in a multi-million dollar investment to create a top-notch screening facility that will elevate the in-vitro biology capabilities of its drug discovery service site at Ahmedabad in India.
The new expansion is expected to take shape in the third quarter of this year itself and will effectively add to the screening capabilities, both primary and secondary of compounds that will be prepared at the site. The benefits from the new investment will come to light as an enhanced experience for customers from PPS discovery services. The statement released by the company said that due to integrated chemistry and biology services available from a single facility, they expect phenomenal improvements in the cycle times of drug discovery.
Besides this, new manpower with experience in the biology gamut is being added to the existing site team, which will complement the currently present, both technical and operational expertise. The statement also added that the new screening technology will enable Piramal to analyze and screen around 1000 compounds in a week via using an array of assay platform technologies like TR-FRET/HTRF, Fluorescent Imaging Plate Reader (FLIPR), absorbance, Luminescence/ Electrochemiluminescence (ECL), Alpha Screen, Lantha Screen, high content imaging, and Cytometry.
On this development, the CEO of Piramal Pharma Solutions, Peter De Young, said that assisting customers when it comes to the discovery process is in synergy with their efforts of being a patient-centric contract development and manufacturing organization. According to him, due to the current investment, they are enhancing their discovery platform by including new in-vitro biology services, thereby making themselves a unified partner.
